Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

PPH Market Vectors Pharmaceutical ETF

  • Fund Description

    Market Vectors® Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors U.S., Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

  •  
      

    • Fund Ticker

      PPH
    • Exchange

      NASDAQ
    • Commencement

      12/20/2011
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      MVPPHTR
    • Index Rebalancing

      Quarterly
  •  
    as of 02/05/16

    • 30-Day SEC Yield1

      2.00%
    • Total Net Assets

      $340.0M
    • Number of Holdings

      26
    • Options

      Available
    • Gross Expense Ratio2

      0.41%
    • Net Expense Ratio/TER2

      0.36%
    • Distribution Frequency

      Quarterly
    • Next Distribution Date

      03/31/2016
  • Key Points

    Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
    Industry Leaders
    Index methodology favors the largest companies in the industry
    Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
     
  • Trading Information

    • Fund Ticker

      PPH
    • Index Total Return Ticker

      MVPPHTR
    • NAV

      PPHNV
    • Intraday NAV (IIV)4

      PPHIV
    • Shares Outstanding

      5,838,138
    • Estimated Cash

      PPHEU
    • Total Cash

      PPHTC
    • CUSIP

      57060U217
    • ISIN

      US57060U2179
    Source: Bloomberg
  • Fees and Expenses2

    • Management Fee

      0.35%
    • Other Expenses

      0.06%
    • Gross Expense Ratio

      0.41%
    • Fee Waivers and
      Expense Reimbursement

      -0.05%
    • Net Expense Ratio/TER2

      0.36%
    2 Expenses for PPH are capped contractually at 0.35% until at least February 1, 2017. Cap excludes certain expenses, such as interest.
  • Prices as of 02/05/16

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    PPH $58.23
    $58.17
    115,524
    69,341
    $-0.72 / -1.22%
    $-0.75 / -1.27%
    -10.4%
    -10.6%
    $-0.06
    -0.11%
  • View All Indices » View All ETFs » Performance History: Average Annual Total Returns* (%)

    1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR LIFE
    12/20/11
    PPH (NAV) -7.02 -6.37 -7.02 -5.72 14.67 -- -- 16.03
    PPH (Share Price) -7.49 -6.87 -7.49 -6.11 14.49 -- -- 16.19
    MVPPHTR (Index) -7.30 -6.37 -7.30 -5.71 14.63 -- -- 15.95
    Performance Differential (NAV - Index) 0.28 0.00 0.28 -0.01 0.04 -- -- 0.08
    Quarter End as of 12/31/15
    1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR LIFE
    12/20/11
    PPH (NAV) 0.91 4.00 3.48 3.48 20.19 -- -- 18.51
    PPH (Share Price) 0.91 4.18 3.58 3.58 20.23 -- -- 18.83
    MVPPHTR (Index) 1.24 4.33 3.43 3.43 20.28 -- -- 18.52
    Performance Differential (NAV - Index) -0.33 -0.33 0.05 0.05 -0.09 -- -- -0.01
  • Daily Holdings »Top 10 Holdings (%)  as of 01/31/16

    Total Holdings: 26
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Johnson & Johnson
    JNJ US
    276,590
    28,887,0608.18
    Novartis Ag
    NVS US
    310,206
    24,186,7626.85
    Glaxosmithkline Plc
    GSK US
    470,011
    19,406,7545.50
    Pfizer Inc
    PFE US
    624,739
    19,048,2925.40
    Sanofi
    SNY US
    441,879
    18,399,8425.21
    Novo Nordisk A/S
    NVO US
    327,856
    18,317,3155.19
    Merck & Co Inc
    MRK US
    352,315
    17,851,8015.06
    Allergan Plc
    AGN US
    60,713
    17,268,5994.89
    Bristol-Myers Squibb Co
    BMY US
    271,207
    16,858,2274.78
    Abbvie Inc
    ABBV US
    298,737
    16,400,6614.65
    Top 10 Total (%)55.71
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 01/31/16

    • Country

      % of Net Assets
    • UNITED STATES

      64.06
    • UNITED KINGDOM

      10.06
    • SWITZERLAND

      6.85
    • FRANCE

      5.21
    • DENMARK

      5.19
    • ISRAEL

      4.45
    • IRELAND

      4.04
    • Other/Cash

      0.13
  • Sector Weightings (%) as of 01/31/16

    • Sector

      % of Net Assets
    • Health Care

      99.9
    • Other/Cash

      0.1